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In a very short period of time radiolabeled peptides
have become an important class of imaging agents for
detection not only of tumors but also of thrombosis and
infection/inflammation (Van Der Laken et al., 2000;
Rennen et al . ,  2001). Somatostatin (SST) is a
multifunctional peptide that is synthesized in
neuroendocrine and other cells present in many tissues and
organs including central and peripheral nervous system,
gastrointestinal tract, endocrine pancreas, thyroid,
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Lanreotide and Octreotide are cyclic octapeptide analogues of
somatostatin that were labeled with the radioisotope Technetium-
99m for use in diagnostic nuclear medicine. The peptides were
processed in a tartrate/phthalate buffer solution containing reducing
agent. The purpose of this investigation was to optimize direct
labeling by varying some parameters, and to evaluate
radiochemical stability and biodistribution in animals. The marked
peptides were obtained with high labeling efficiency and no need
for subsequent purification. Best radiolabeling results corresponded
to a molar ratio of SnCl2.H2O/peptide of 4.5. 
99mTc-peptides were
radiochemically stable for 6 hours. 99mTc-octreotide was relatively
more susceptible to cysteine challenge than 99mTc-lanreotide. 99mTc-
peptides were mainly distributed in the gastrointestinal tract but
99mTc-lanreotide showed a greater uptake by the liver than 99mTc-
octreotide.  Results indicated that the products can be obtained
with high radiochemical yield, in a simple routine appropriate for
further studies to assess their efficacy in radiodiagnosis.
adrenals, genitourinary tract and lymphatic tissue. There
are a number of somastostatin-related radiopharma-
ceuticals available today, especially for visualization of
neuroendocrine tumours (Angetti et al., 1998; Leners et
al., 1996; Oppizi et al., 1998; Signore et al., 1995).
The first clinical research using radiolabeled
somatostatin analogues was performed by Lamberts et al.
(1990). Historically, somatostatin analogs were the first
class of receptor-binding peptides to gain clinical
application. Lamberts et al. (1990) used 123I-Tyr3-octreo
tide to localize somatostatin receptor-bearing tumors.
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However this product showed some disadvantages in
clinical practice such as limited availability, high cost and
high intestinal radioactivity due to hepatobiliary clearance
(Krenning et al., 1992). Consequently a new tracer
was developed, namely 111In-DTPA-octreotide
(Octreoscan-Mallinckrodt Inc.), that displayed high
sensitivity for diagnosis of both primary and metastatic
tumor lesions.
111In-DTPA-[D-Phe1]-octreotide is the first
radiopeptide which has obtained regulatory approval in
Europe and the United States. Although Octreoscan is
widely used for imaging somatostatin receptors, the use of
111In imposes some limitations, due to its suboptimal
imaging characteristics, high cost and limited availability.
As far as diagnostic imaging is concerned, technetium-
99m continues to be the most widely used radionuclide.
99mTc-Apcitide and 99mTc-Depreotide also received
regulatory approval. The former is used for acute
thrombosis and the latter is used for the differentiation
between benign lesions and pulmonary neoplasia, based
on expression of somatostatin receptors (Weiner et al.,
2002).
Technetium-99m has been used in the last decade to
label many kits. Its nuclear features of 6-hour half-life and
gamma energy of 140 keV make it one of the best
radionuclides as regards imaging qualities, with a half-
time long enough to permit complete studies without an
unnecessary dose of radiation. It is easily available by
elution in isotonic saline from a 99Mo/99mTc generator.
The challenge of radiolabeling is to obtain a
complex that maintains the biological activity of the
peptide. 99mTc labeling of somatostatin analogues has been
extensively studied, including attempts at direct labeling
after reduction of the disulfide bridge (Kolan et al., 1996;
Haberberger et al., 1995; Thakur et al., 1996) and the use
of bifunctional chelates (Hnatowich et al., 1998; Baidoo
et al., 1998).
Lanreotide [D-(Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-
Thr.NH2] as well as octreotide [H2N-D-Phe-Cys-Phe-D-
Trp-Lys-Thr-Cys-Thr(OH)] are synthetic octapeptide
analogs of the native hormone somatostatin, produced by
the hypothalamus and pancreas (Smith-Jones et al., 1999).
They are cyclized via cysteine bridge.
Lanreotide and octreotide are widely used for the
symptomatic treatment of neuroendocrine-active tumors,
such as growth hormone-producing pituitary adenomas
and gastroenteropancreatic tumors (Arnold et al., 2000).
Preparation of 99mTc-labeled octapeptides, namely
octreotide and lanreotide, analysis of their radiochemical
purity and stability, as well as the biodistribution pattern
in animals were the aims of the current investigation.
MATERIAL AND METHODS
Material
Lanreotide 8–mer was obtained from Pi-Chem
(Graz, Austria) provided by the International Atomic
Energy Agency (IAEA) and octreotide was a generous gift
of Novartis (São Paulo, Brazil). Technetium-99m was
obtained from an alumina-based 99Mo/99mTc generator
locally supplied by Institute of Energetic and Nuclear
Research (IPEN/CNEN) - São Paulo, Brazil.
Methods
Preparation of Peptides
Each preparation and labeling procedure was
identical for both peptides and all solutions were nitrogen-
purged. In brief, 2.5 mg of the peptide was dissolved in
water and distributed in many vials in different samples
(10 to 100 mg) that were frozen at -30 °C until use. To a
vial containing the peptide a small volume of a solution
containing 20 mM tartrate, 80 mM phthalate, 4% maltose,
and 100 mM glycine was added. A solution of stannous
chloride in HCl 0.1 N based on the defined molar ratio of
SnCl2.2H20/peptide was also introduced in the mixture.
After allowing the preparation to react at room
temperature for 4 h with continuous rotation, the resulting
solution was stored frozen at – 30 °C until use or
immediately labeled.
Radiolabeling
99mTc was obtained from the column of the generator
by elution with 6 ml of 0.9% sodium chloride injection.
99mTc (37-370 MBq) was added to the peptide mixture
prepared as above. The solution was heated for 15 minutes
in a water bath at 100 °C and then left at room temperature
to cool.
Radiochemical Control
Radiochemical analysis of 99mTc-peptides was
performed by thin-layer chromatography (TLC) to deter-
mine labeling efficiency and colloid formation. Instant
Thin Layer Chromatography – Silica Gel (ITLC-SG)
chromatography paper was cut into 1.5 x 13cm strips and
activated by heating for 30 min, at 110 °C, according to the
manufacturer instructions.
Labeling efficiency was determined using acidified
ethanol 85% and saline 0.9% as the mobile phase. The
radioactivity of the strips was analyzed in
radiochromatography equipment (Berthold, Belgium).
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Optimization of Radiolabeling
Optimization was achieved by varying parameters
including peptide mass (10, 50, 100 mg), stannous
chloride/peptide molar ratio (1.8, 2.7, 3.6, 4.5) and
reaction time (0.5 and 1.0 hour). Radiochemical stability
of the complex was observed until 6 hours.
Cysteine Challenge
Bond strength of 99mTc peptide complexes was
evaluated by displacement of bound radionuclide with
cysteine (Rhodes et al., 1995). Known amounts of 99mTc-
lanreotide and 99mTc-octreotide were challenged over a
range of cysteine concentrations (0.1 mM to 100 mM) at
37 °C for 1 hour. The percentage of 99mTc displaced by
cysteine was determined by TLC using 0.9% saline as
mobile phase, and the amount of displaced radiolabel
found at the solvent front was determined.
Biodistribution studies
Experiments were carried out in compliance with
the guidelines for conduct in animal experimentation,
Scientific Ethics Committee, IPEN/CNEN-SP.
Invasive biodistribution assessment was done in
groups of six Swiss mice by intravenous injection of 0.1
ml of radiolabeled peptides with 3.7 MBq of 99mTc.
Animals were sacrificed after injection and organs were
removed, weighed and radioactivity was determined in a
well-type gamma counter. Radioactivity was also
measured in blood samples. The results were expressed as
percentage of injected dose per gram of tissue.
Dynamic imaging studies were performed in Wistar
rats (4 animals/group) at the first 10 minutes of
administration of each drug and static imaging after 15
min, 2, 4 and 6 hours post injection.
RESULTS
Peptide labeling with technetium-99m by direct method
Labeling efficiency determined by thin-layer
chromatography with 0.9% saline as a mobile phase
showed that unbound radioactivity migrated with the
solvent front, while bound radioactivity remained at the
origin (Figure 1).
Amount of colloids formed in the peptide solution
was determined using 85% ethanol as a mobile phase.
Radiolabeled peptides moved to the solvent front and
colloids remained at the origin (Figure 2).
The first study with 99mTc was made varying the
amount of stannous chloride in the labeling of octreotide
in tartrate/phtalate buffer solution (Figure 3).
It had been previously observed that with 10 mg of
SnCl2.H2O the peptide was not labeled. The amount was
insufficient to reduce cysteine bridges and technetium, so
the reaction did not occur.
When the molar ratio between reducing agent and
peptide (octreotide) was low the resulting yield was also
low. The best finding was for a molar ratio of 4.5 (Table I).
Labeling of lanreotide with 99mTc was investigated
on the basis of the results obtained with 99mTc-octreotide.
FIGURE 1 – Radiochromatogram of 99mTc-lanreotide in saline 0.9%.
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FIGURE 2 – Radiochromatogram of 99mTc-lanreotide in ethanol 85% as solvent.
FIGURE 3 - Labeling efficiency of 99mTc-octreotide.
TABLE 1 – Radiochemical purity of 99mTc-octreotide varying the molar ratio of SnCl2.H2O/octreotide
SnCl2.H2O/octreotide % 99mTcO4 % 99mTcO2 % 99mTc-octreotide
1.8 91.0 ± 0.4 2.9 ± 0.3 6.0 ± 0.8
2.7 30.5 ± 1.1 1.9 ± 0.6 67.6 ± 1.6
3.6 48.9 ± 1.9 1.0 ± 0.3 50.1 ± 2.3
4.5 3.5 ±1.9 1.4 ±0.1 95.1 ±2.0
Octreotide = 50 µg
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So, we observed that the best molar ratio between
SnCl2.H20.2H2O/lanreotide was 4.9 for a mass of
lanreotide and a mass of stannous chloride above 50 mg
(Figure 4).
Both 99mTc-octreotide or 99mTc-lanreotide were
radiochemically stable for 6 hours (Table 2). However
99mTc-octreotide had a loss in radiochemical purity of
3.9%.
Transchelation to cysteine was studied at five molar
ratios (Figure 5). It was observed that 99mTc-octreotide was
relatively more susceptible to Cys challenge than 99mTc-
lanreotide.
TABLE 2 – Radiochemical stability. Tested amounts were:
for mlanreotide, 50 µg; for moctreotide , 50 µg and for mSnCl2.2H2O
also 50 µg
Time % Radiochemical % Radiochemical
(hours) Purity Purity
99mTc-octreotide 99mTc-lanreotide
0 95.1 ± 2.0 97.9 ± 0.9
2 92.1 ± 1.0 96.2 ± 1.7
4 95.9 ± 0.6 97.3 ± 0.8
6 91.2 ± 0.3 96.7 ± 1.3
FIGURE 4 - Radiochemical efficiency of 99mTc-lanreotide.
FIGURE 5 - Percent dissociation of 99mTc from the peptides vs. Cys concentration.




Preliminary biodistribution of 99mTc-lanreotide and
99mTc-octreotide was assessed in normal Wistar rats by
dynamic imaging techniques during the first 10 minutes
after injection (Figure 6) and by static imaging at 15 min
(Figure 7), 1, 2 and 4 hours post injection. No differences
were observed, in static images, among these times.
Invasive studies were done in Swiss mice and the
results can be observed in Figure 8 and Figure 9. 99mTc-
labeled peptides localized in the gastrointestinal tract or in
the kidney. For 99mTc-octreotide the greatest uptake
corresponded to small intestine and kidneys (Figure 8).
99mTc-lanreotide exhibited highest affinity for the liver in
the first 15 min post injection, and no clearance of blood
FIGURE 6 - Dynamic imaging of 99mTc-octreotide in the first 10 minutes. Acquisition time for each image was 37.5
seconds, and sequence was from left to right and from top to bottom line.
FIGURE 7 - Static imaging of 99mTc-octreotide at 15 min post-injection.
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could be detected during 6 hours (Figure 9). This was true
for 99mTc-octreotide as well (Figure 8). Other organs
involved in uptake or clearance were kidneys, small
intestine and lungs.
DISCUSSION
Somatostatin analogues, namely octreotide,
lanreotide and others, were developed because the native
peptide is susceptible to very rapid enzymatic degradation.
FIGURE 8 - Biodistribution of 99mTc-octreotide.
FIGURE 9 - Biodistribution of 99mTc-lanreotide.
The major challenge to label peptides with 99mTc is
to obtain a product that doesn’t loose receptor binding
affinity or specificity. The peptide must be designed to be
resistant to proteases.
Labeling can be done by direct method when
cyclized peptide molecules are employed, based upon the
reduction of disulfide bridge. The indirect method
depends on a bifunctional chelating agent which is
chemically coupled to the terminal amino groups of (D)
phenylalanine. During this procedure, other functional
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groups are blocked and then deblocked. Often after
radiolabeling the radiopharmaceutical must be purified.
The steps require time and additional cost.
The direct method is a simple procedure since it
eliminates the need for peptide conjugation with an
exogenous chelator (Thakur et al., 1996).
Although it is considered necessary to use cyclized
cisteine for the direct labeling method, and that cyclization
confers resistance to proteolysis, the reduction of the
cysteine bridge can inactivate the peptide. But, studies
done with octreotide and with RC-160 with 99mTc and 186Re
have not shown any apparent loss of biological activity
(Haberberger et al., 1995) encouraging the use of this
method.
In the current protocol, radiochemical purity of
99mTc-peptides was strongly linked to molar ratio between
reducing agent and peptide. The involvement of tin in
protein labeling as a tin-protein intermediate was
suggested by Rhodes (1991).For a pretinning procedure,
the reduction of native disulfide bridges is carried out by
incubating the protein with stannous ions. Technetium-
99m available in the 7+ oxidation state as 99mTcO4
- must be
reduced to a lower oxidation state, and that can be done
using the same reducing agent, stannous chloride. In the
procedure, as the thiol protecting group is removed, the
mixture needs to be heated due to the slow labeling
kinetics at room temperature (Okarvi, 1999).
Transchelation studies evaluated the bond strength
of the 99mTc-peptide complexes upon the presence of
cysteine in body. Maximum concentration of cysteine to
which the peptide is expected to be exposed in vivo is 1
mM (Cooper, 1983). The high molar ratio demonstrated to
cause displacement suggests that bond strength of the
99mTc-peptides was very high.
The highest rate of transchelation observed in our
study, for 99mTc-lanreotide, was 13% at 100 mM of
cysteine, in comparison with 70% observed by Pervez et
al., 2001, for the same concentration of cysteine.
In biodistribution studies it had been documented
that main organ uptake by 99mTc-lanreotide was liver, from
where it was cleared to small intestine, whereas for 99mTc-
octreotide small intestine came first, followed by
clearance to kidneys. The difference between both
complexes is due to different structures (amino acid
sequence) that influence lipophilicity and biodistribution.
Blood values remained unaltered (approximately
0.5% ID/mL) during 6 hours post injection (p.i.); similar
to the findings obtained for 99mTc-sandostatin 0.3 %ID/
mL, 24 hours p.i., by Kolan et al. (1996).
In addition to lipophilicity, stability of the complex
also seems to be an important factor influencing
biodistribution. Lanreotide is more lipophilic than
octreotide and is very similar to another fully studied
agent, vapreotide (RC-160), with differences in the
extremes of the molecule.
CONCLUSION
Labeling of both peptides with 99mTc by direct
method was simple and efficient, with a high labeling
yield, stability in face of cysteine challenge, and an
interesting biodistribution pattern. Lanreotide and
Octreotide are cyclic octapeptide analogues of
somatostatin that were labeled with the radioisotope
technetium-99m for future use in diagnostic nuclear
medicine. The peptides were processed in a tartrate/
phthalate buffer solution containing reducing agent. The
purpose of this investigation was to optimize direct
labeling by varying some parameters, and to evaluate
radiochemical stability and biodistribution in animals. The
marked peptides were obtained with high labeling
efficiency and no need for subsequent purification. Best
radiolabeling results corresponded to a molar ratio of
SnCl2.H2O/peptide of 4.5. 
99mTc-peptides were
radiochemically stable for 6 hours. 99mTc-octreotide was
relatively more susceptible to cysteine challenge than
99mTc-lanreotide. 99mTc-peptides were mainly distributed in
the gastrointestinal tract but 99mTc-lanreotide showed a
greater uptake by the liver than 99mTc-octreotide. Results
indicated that the products can be obtained with high
radiochemical yield, in a simple routine appropriate for
further studies to assess their efficacy in radiodiagnosis.
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RESUMO
Lanreotídeo e octreotídeo complexados com
tecnécio-99m: estudo de marcação estabilidade
e estudos de biodistribuição
Lanreotídeo e octreotídeo são octapeptídeos cíclicos aná-
logos da somatostatina e têm sido marcados com
Tecnécio-99m para uso em diagnóstico na Medicina Nu-
clear. Os peptídeos são preparados em solução tampão
ftalato/tartarato contendo um agente redutor. O objetivo
deste estudo foi a otimização da marcação direta variando
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alguns parâmetros e a avaliação da estabilidade
radioquímica e biodistribuição em animais. Os peptídeos
marcados foram obtidos com alta eficiência de marcação
e sem a necessidade de etapa de purificação no final do
processo. Os melhores resultados de radiomarcação
corresponderam á razão molar de SnCl2.2H2O/peptídeo
de 4,5. Os peptídeos-99mTc mostraram-se radio-
quimicamente estáveis por 6 horas. Octreotídeo-99mTc
mostrou-se relativamente mais suscetível frente à cisteína
do que o lanreotídeo-99mTc. Os peptídeos-99mTc foram prin-
cipalmente distribuídos no trato gastrointestinal, porém o
lanreotídeo-99mTc mostrou maior captação pelo fígado do
que o octreotídeo-99mTc. Os resultados indicaram que os
produtos podem ser obtidos com alto rendimento
radioquímico e com procedimento simples, permitindo
estudos posteriores para avaliação de sua eficácia em
radiodiagnóstico.
UNITERMOS: Tecnécio-99m. Radiomarcação.
Peptídeos. Somatostatina. Octreotídeo. Lanreotídeo.
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